Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Adaptimmune Therapeutics

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

Adapti Inc

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

Press Releases

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Reports Q2 Financial Results and Provides Business Update

ADAP

AFFX

Abpro Hldgs

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Edesa Biotech

Evaxion

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

Imunon

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kairos Pharma

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lisata Therapeutics

Moleculin Biotech

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Portage Biotech

SAB Biotherapeutics

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Synlogic

TAO Synergies

Mizuho

Barclays

Wells Fargo

Guggenheim

Scotiabank

Adaptive Brdbnd

Comments

Adaptimmune Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL